Delivery of therapeutic proteins to the mucosa using genetically modified microflora

Expert Opinion on Drug Delivery

Volumn 2, Issue 4, 2005, Pages 737-746

  Steidler, Lothar ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antibiotics; Cytokines; Genetically modified microflora; Mucosa; Therapeutic proteins

Indexed keywords

CD4 ANTIGEN; CYTOKINE; FLUCONAZOLE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTESTINAL TREFOIL FACTOR; NEUTRALIZING ANTIBODY; PROBIOTIC AGENT; PROTEIN DERIVATIVE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETANUS TOXOID; THYMIDINE; THYMIDYLATE SYNTHASE; THYMINE; TRIACYLGLYCEROL LIPASE;

ANTIBIOTIC RESISTANCE; AUXOTROPHY; BACTERIAL COLONIZATION; CANDIDIASIS; CLOSTRIDIUM DIFFICILE; CROHN DISEASE; DAIRY PRODUCT; DNA MODIFICATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; ENTERITIS; GENETIC ENGINEERING; INTESTINE MUCOSA; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; MICROFLORA; MOUTH MUCOSA; NONHUMAN; NOSE MUCOSA; PASSIVE IMMUNIZATION; REVIEW; SOCIAL ASPECT; STREPTOCOCCUS GORDONII; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TETANUS; ULCERATIVE COLITIS; VAGINA MUCOSA; VAGINITIS;

ANIMALS; ANTIBODIES; BACTERIA; CYTOKINES; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC ENGINEERING; HUMANS; INTESTINAL MUCOSA; MOUTH MUCOSA; NASAL MUCOSA; PROTEINS; VAGINA;

EID: 22844433585     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.4.737     Document Type: Review

References (74)

1. THOMAS C, STEVENSON M, RILEY TV: Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J. Antimicrob. Chemother. (2003) 51(6):1339-1350.
2. ZHOU X, BENT SJ, SCHNEIDER MG et al.: Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology (2004) 150(8):2565-2573.
3. REID G, BURTON J, HAMMOND JA, BRUCE AW: Nucleic acid-based diagnosis of bacterial vaginosis and improved management using probiotic lactobacilli. J. Med. Food (2004) 7(2):223-228.
4. BACKHED F, DING H, WANG T et al.: The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA (2004) 101(44):15718-15723.
5. AHMED FE: Genetically modified probiotics in foods. Trends Biotech. (2003) 21(11):491-497.
6. KLEEREBEZEM M, HUGENHOLTZ J: Metabolic pathway engineering in lactic acid bacteria. Curr. Opin. Biotechnol. (2003) 14(2):232-237.
7. SEEGERS JF: Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotech. (2002) 20(12):508-515.
8. NOUAILLE S, RIBEIRO LA, MIYOSHI A et al.: Heterologous protein production and delivery systems for Lactococcus lactis. Genet. Mol. Res. (2003) 2(1):102-111.
9. WELLS JM, WILSON PW, NORTON PM, GASSON MJ, LE PAGE RW: Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. (1993) 8(6):1155-1162.
10. NORTON PM, WELLS JM, BROWN HW, MACPHERSON AM, LE PAGE RW: Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine (1997) 15(6-7):616-619.
11. ROBINSON K, CHAMBERLAIN LM, SCHOFIELD KM, WELLS JM, LE PAGE RW: Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. (1997) 15(7):653-657.
12. MANNAM P, JONES KF, GELLER BL: Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect. Immun. (2004) 72(6):3444-3450.
13. STEIDLER L, WELLS JM, RAEYMAEKERS A et al.: Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis. Appl. Environ. Microbiol. (1995) 61(4):1627-1629.
14. STEIDLER L, ROBINSON K, CHAMBERLAIN L et al.: Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect. Immun. (1998) 66(7):3183-3189.
15. STEIDLER L, HANS W, SCHOTTE L et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289(5483):1352-1355.
16. SCHOTTE L, STEIDLER L, VANDEKERCKHOVE J, REMAUT E: Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb. Technol. (2000) 27(10):761-765.
17. MERTENS N, REMAUT E, FIERS W: Tight transcriptional control mechanism ensures stable high-level expression from T7 promoter-based expression plasmids. Biotechnology (1995) 13(2):175-179.
18. GUISEZ Y, DEMOLDER J, MERTENS N et al.: High-level expression, purification, and renaturation of recombinant murine interleukin-2 from Escherichia coli. Protein Expr. Purif. (1993) 4(3):240-246.
19. DERYNCK R, REMAUT E, SAMAN E et al.: Expression of human fibroblast interferon gene in Escherichia coli. Nature (1980) 287(5779):193-197.
20. STEIDLER L, FIERS W, REMAUT E: Expression of human and murine interleukins in Lactococcus lactis. In: Metabolism and Application of Lactic Acid Bacteria. B Ray, F Bozoglu (Eds), Springer-Verlag, New York, USA (1996):63-79.
21. RONG Y, LEE N, LLANG SM: Analysis of IL-2 functional structure by multiple cysteine substitutions. Biochem. Biophys. Res. Commun. (1992) 188(2):949-955.
22. ZHANG JG, MATTHEWS JM, WARD LD, SIMPSON RJ: Disruption of the disulfide bonds of recombinant murine interleukin-6 induces formation of a partially unfolded state. Biochemistry (1997) 36(9):2380-2389.
23. WINDSOR WT, SYTO R, TSARBOPOULOS A et al.: Disulfide bond assignments and secondary structure analysis of human and murine interleukin 10. Biochemistry (1993) 32(34):8807-8815.
24. CHADWICK MP, MAY FE, WESTLEY BR: Production and comparison of mature single-domain 'trefoil' peptides pNR-2/pS2 Cys58 and pNR-2/pS2 Ser58. Biochem. J. (1995) 308(Pt 3):1001-1007.
25. STEIDLER L, NEIRYNCK S, HUYGHEBAERT N et al.: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. (2003) 21(7):785-789.
26. VANDENBROUCKE K, HANS W, VAN HUYSSE J et al.: Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology (2004) 127(2):502-513.
27. DROUAULT S, JUSTE C, MARTEAU P, RENAULT P, CORTHIER G: Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl. Environ. Microbiol. (2002) 68(6):3166-3168.
28. SARTOR RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology (2004) 126(6):1620-1633.
29. THOMPSON C, POWRIE F: Regulatory T cells. Curr. Opin. Pharmacol. (2004) 4(4):408-414.
30. BLUESTONE JA, ABBAS AK: Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. (2003) 3(3):253-257.
31. BRAAT H, PEPPELENBOSCH MP, HOMMES DW: Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin. Biol. Ther. (2003) 3(5):725-731.
32. VAN DEVENTER SJ, ELSON CO, FEDORAK RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology (1997) 113(2):383-389.
33. FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group. Gastroenterology (2000) 119(6):1473-1482.
34. SCHREIBER S: Genetics of inflammatory bowel disease: a puzzle with contradictions? Gut (2000) 47(6):746-747.
35. TILG H, ULMER H, KASER A, WEISS G: Role of IL-10 for induction of anemia during inflammation. J. Immunol. (2002) 169(4):2204-2209.
36. TAUPIN DR, PANG KC, GREEN SP, GIRAUD AS: The trefoil peptides spasmolytic polypeptide and intestinal trefoil factor are major secretory products of the rat gut. Peptides (1995) 16(6):1001-1005.
37. POULSEN SS, THULESEN J, CHRISTENSEN L, NEXO E, THIM L: Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut (1999) 45(4):516-522.
38. THIM L, MORTZ E: Isolation and characterization of putative trefoil peptide receptors. Regul. Pept. (2000) 90(1-3):61-68.
39. TAN XD, CHEN YH, LIU QP, GONZALEZ-CRUSSI F, LIU XL: Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: role of cyclooxygenase-2. J. Cell Sci. (2000) 113(12):2149-2155.
40. RODRIGUES S, VAN AKEN E, VAN BOCXLAER S et al.: Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J. (2003) 17(1):7-16.
41. RICCI S, MACCHIA G, RUGGIERO P et al.: In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol. (2003) 3(1):15.
42. FIDEL PL Jr, SOBEL JD: Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin. Microbiol. Rev. (1996) 9(3):335-348.
43. MEDAGLINI D, RUSH CM, SESTINI P, POZZI G: Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice. Vaccine (1997) 15(12-13):1330-1337.
44. MEDAGLINI D, OGGIONI MR, POZZI G: Vaginal immunization with recombinant Gram-positive bacteria. Am. J. Reprod. Immunol. (1998) 39(3):199-208.
45. DI FABIO S, MEDAGLINI D, RUSH CM et al.: Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine (1998) 16(5):485-492.
46. BENINATI C, OGGIONI MR, BOCCANERA M et al.: Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol. (2000) 18(10):1060-1064.
47. MAGLIANI W, CONTI S, DE BERNARDIS F et al.: Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. (1997) 15(2):155-158.
48. POLONELLI L, MORACE G: Production and characterization of yeast killer toxin monoclonal antibodies. J. Clin. Microbiol. (1987) 25(2):460-462.
49. CHANG TLY, CHANG CH, SIMPSON DA et al.: Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl. Acad. Sci. USA (2003) 100(20):11672-11677.
50. LEHNER T, CALDWELL J, SMITH R: Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries. Infect. Immun. (1985) 50(3):796-799.
51. MICHALEK SM, GREGORY RL, HARMON CC et al.: Protection of gnotobiotic rats against dental caries by passive immunization with bovine milk antibodies to Streptococcus mutans. Infect. Immun. (1987) 55(10):2341-2347.
52. KRUGER C, HU Y, PAN Q et al.: In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat. Biotechnol. (2002) 20(7):702-706.
53. HILLMAN JD, BROOKS TA, MICHALEK SM et al.: Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect. Immun. (2000) 68(2):543-549.
54. HILLMAN JD, JOHNSON KP, YAPHE BI: Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect. Immun. (1984) 44(1):141-144.
55. HILLMAN JD, NOVAK J, SAGURA E et al.: Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect. Immun. (1998) 66(6):2743-2749.
56. HILLMAN JD, DZUBACK AL, ANDREWS SW: Colonization of the human oral cavity by a Streptococcus mutans mutant producing increased bacteriocin. J. Dent. Res. (1987) 66(6):1092-1094.
57. ANDERSON MH: Changing paradigms in caries management. Curr. Opin. Dent. (1992) 2:57-162.
58. HILLMAN JD: Genetically modified Streptococcus mutans for the prevention of dental caries. Antonie Van Leeuwenhoek (2002) 82(1-4):361-366.
59. BERMUDEZ-HUMARAN LG, LANGELLA P, CORTES-PEREZ NG et al.: Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect. Immun. (2003) 71(4):1887-1896.
60. LING P, GATELY MK, GUBLER U et al.: Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J. Immunol. (1995) 154(1):116-127.
61. PLATTEEUW C, VAN ALEN-BOERRIGTER I, VAN SCHALKWIJK S, DE VOS WM: Food-grade cloning and expression system for Lactococcus lactis. Appl. Environ. Microbiol. (1996) 62(3):1008-1013.
62. LEENHOUTS K, BOLHUIS A, VENEMA G, KOK J: Construction of a food-grade multiple-copy integration system for Lactococcus lactis. Appl. Microbiol. Biotechnol. (1998) 49(4):417-423.
63. SORENSEN KI, LARSEN R, KIBENICH A, JUNGE MP, JOHANSEN E: A food-grade cloning system for industrial strains of Lactococcus lactis. Appl. Environ. Microbiol. (2000) 66(4):1253-1258.
64. BRON PA, BENCHIMOL MG, LAMBERT J et al.: Use of the alr gene as a food-grade selection marker in lactic acid bacteria. Appl. Environ. Microbiol. (2002) 68(11):5663-5670.
65. HOLS P, DEFRENNE C, FERAIN T et al.: The alanine racemase gene is essential for growth of Lactobacillus plantarum. J. Bacteriol. (1997) 179(11):3804-3807.
66. MOLIN S, BOE L, JENSEN LB et al.: Suicidal genetic elements and their use in biological containment of bacteria. Ann. Rev. Microbiol. (1993) 47:139-166.
67. JENSEN LB, RAMOS JL, KANEVA Z, MOLIN S: A substrate-dependent biological containment system for Pseudomonas putida based on the Escherichia coli gef gene. Appl. Environ. Microbiol. (1993) 59(11):3713-3717.
68. KNUDSEN S, SAADBYE P, HANSEN LH et al.: Development and testing of improved suicide functions for biological containment of bacteria. Appl. Environ. Microbiol. (1995) 61(3):985-991.
69. RECORBET G, ROBERT C, GIVAUDAN A et al.: Conditional suicide system of Escherichia coli released into soil that uses the Bacillus subtilis sacB gene. Appl. Environ. Microbiol. (1993) 59(5):1361-1366.
70. MOLINA L, RAMOS C, RONCHEL MC, MOLIN S, RAMOS JL: Construction of an efficient biologically contained pseudomonas putida strain and its survival in outdoor assays. Appl. Environ. Microbiol. (1998) 64(6):2072-2078.
71. AHMAD SI, KIRK SH, EISENSTARK A: Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Ann. Rev. Microbiol. (1998) 52:591-625.
72. ALPERT C-A, MATER DD, MULLER M-C et al.: Worst-case scenarios for horizontal gene transfer from Lactococcus lactis carrying heterologous genes to Enterococcus faecalis in the digestive tract of gnotobiotic mice. Environ. Biosafety Res. (2004) 2:173-180.
73. HUYGHEBAERT N, VERMEIRE A, NEIRYNCK S et al.: Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis. Eur. J. Pharm. Biopharm. (2005) 59(1):9-15.
74. BRON PA, GRANGETTE C, MERCENIER A, DE VOS WM, KLEEREBEZEM M: Identification of Lactobacillus plantarum genes that are induced in the gastrointestinal tract of mice. J. Bacteriol. (2004) 186(17):5721-5729.